2019 Future of Ischemia Reperfusion Injury R&D Pipeline Drugs and Companies- Analysis of Global Ischemia Reperfusion Injury Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Ischemia Reperfusion Injury treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Ischemia Reperfusion Injury pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Ischemia Reperfusion Injury pipeline companies from advancing their products into Phase 3 or Phase 4.
Ischemia Reperfusion Injury Report Description
The H1 2019 pipeline review report on Ischemia Reperfusion Injury pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Ischemia Reperfusion Injury pipeline compounds.
The Ischemia Reperfusion Injury pipeline guide presents information on all active drugs currently being developed for Ischemia Reperfusion Injury. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Ischemia Reperfusion Injury pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Ischemia Reperfusion Injury drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Ischemia Reperfusion Injury product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Ischemia Reperfusion Injury pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Ischemia Reperfusion Injury pipeline report includes
REASONS TO BUY
Ischemia Reperfusion Injury Report Description
The H1 2019 pipeline review report on Ischemia Reperfusion Injury pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Ischemia Reperfusion Injury pipeline compounds.
The Ischemia Reperfusion Injury pipeline guide presents information on all active drugs currently being developed for Ischemia Reperfusion Injury. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Ischemia Reperfusion Injury pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Ischemia Reperfusion Injury drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Ischemia Reperfusion Injury product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Ischemia Reperfusion Injury pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Ischemia Reperfusion Injury pipeline report includes
- An overview of Ischemia Reperfusion Injury disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of pipeline compounds
- Company wise list of pipeline compounds
- Mechanism of Action wise pipeline compounds
- For each pipeline product, the following details are provided-
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials
REASONS TO BUY
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Ischemia Reperfusion Injury pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Ischemia Reperfusion Injury pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into the market through in-depth strategic analysis review
- Know the list of companies participating in global Ischemia Reperfusion Injury pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL ISCHEMIA REPERFUSION INJURY PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Ischemia Reperfusion Injury Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Ischemia Reperfusion Injury pipeline, H1- 2019
3.5 Mechanism of Action wise Ischemia Reperfusion Injury Pipeline Candidates
4. ACELEROX LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
4.1 Acelerox LLC Business Profile
4.2 Acelerox LLC Ischemia Reperfusion Injury Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. AMYNDAS PHARMACEUTICALS LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
5.1 Amyndas Pharmaceuticals LLC Business Profile
5.2 Amyndas Pharmaceuticals LLC Ischemia Reperfusion Injury Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. ANGION BIOMEDICA CORP ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
6.1 Angion Biomedica Corp Business Profile
6.2 Angion Biomedica Corp Ischemia Reperfusion Injury Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. ARCH ONCOLOGY ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
7.1 Arch Oncology Business Profile
7.2 Arch Oncology Ischemia Reperfusion Injury Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. ARMARON BIO PTY LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
8.1 Armaron Bio Pty Ltd Business Profile
8.2 Armaron Bio Pty Ltd Ischemia Reperfusion Injury Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. BIOMEDCORE INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
9.1 BioMedCore Inc Business Profile
9.2 BioMedCore Inc Ischemia Reperfusion Injury Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. BOLDER BIOTECHNOLOGY INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
10.1 Bolder Biotechnology Inc Business Profile
10.2 Bolder Biotechnology Inc Ischemia Reperfusion Injury Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. CATALYST BIOSCIENCES INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
11.1 Catalyst Biosciences Inc Business Profile
11.2 Catalyst Biosciences Inc Ischemia Reperfusion Injury Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. CELDARA MEDICAL LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
12.1 Celdara Medical LLC Business Profile
12.2 Celdara Medical LLC Ischemia Reperfusion Injury Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. CELLMID LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
13.1 Cellmid Ltd Business Profile
13.2 Cellmid Ltd Ischemia Reperfusion Injury Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. CFM PHARMA HOLDING BV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
14.1 CFM Pharma Holding BV Business Profile
14.2 CFM Pharma Holding BV Ischemia Reperfusion Injury Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. CONATUS PHARMACEUTICALS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
15.1 Conatus Pharmaceuticals Inc Business Profile
15.2 Conatus Pharmaceuticals Inc Ischemia Reperfusion Injury Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. CORLINE BIOMEDICAL AB ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
16.1 Corline Biomedical AB Business Profile
16.2 Corline Biomedical AB Ischemia Reperfusion Injury Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. FARADAY PHARMACEUTICALS ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
17.1 Faraday Pharmaceuticals Business Profile
17.2 Faraday Pharmaceuticals Ischemia Reperfusion Injury Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. GLUCOX BIOTECH AB ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
18.1 Glucox Biotech AB Business Profile
18.2 Glucox Biotech AB Ischemia Reperfusion Injury Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19. ISCHEMIX INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
19.1 Ischemix Inc Business Profile
19.2 Ischemix Inc Ischemia Reperfusion Injury Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20. MALLINCKRODT PLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
20.1 MallInckrodt Plc Business Profile
20.2 MallInckrodt Plc Ischemia Reperfusion Injury Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
21. MIRAGEN THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
21.1 Miragen Therapeutics Inc Business Profile
21.2 Miragen Therapeutics Inc Ischemia Reperfusion Injury Drug Details
21.2.1 Drug Snapshot
21.2.1.1 Originator
21.2.1.2 Collaborator/Co-Developer
21.2.1.3 Route of Administration
21.2.1.4 Orphan Drug/Fast Track/Special Designation
21.2.1.5 Area
21.2.1.6 Type of Molecular Entity
21.3 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments
22. NOVELMED THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
22.1 NovelMed Therapeutics Inc Business Profile
22.2 NovelMed Therapeutics Inc Ischemia Reperfusion Injury Drug Details
22.2.1 Drug Snapshot
22.2.1.1 Originator
22.2.1.2 Collaborator/Co-Developer
22.2.1.3 Route of Administration
22.2.1.4 Orphan Drug/Fast Track/Special Designation
22.2.1.5 Area
22.2.1.6 Type of Molecular Entity
22.3 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments
23. OPSONA THERAPEUTICS LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
23.1 Opsona Therapeutics Ltd Business Profile
23.2 Opsona Therapeutics Ltd Ischemia Reperfusion Injury Drug Details
23.2.1 Drug Snapshot
23.2.1.1 Originator
23.2.1.2 Collaborator/Co-Developer
23.2.1.3 Route of Administration
23.2.1.4 Orphan Drug/Fast Track/Special Designation
23.2.1.5 Area
23.2.1.6 Type of Molecular Entity
23.3 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments
24. PHARMING GROUP NV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
24.1 Pharming Group NV Business Profile
24.2 Pharming Group NV Ischemia Reperfusion Injury Drug Details
24.2.1 Drug Snapshot
24.2.1.1 Originator
24.2.1.2 Collaborator/Co-Developer
24.2.1.3 Route of Administration
24.2.1.4 Orphan Drug/Fast Track/Special Designation
24.2.1.5 Area
24.2.1.6 Type of Molecular Entity
24.3 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments
25. PROLONG PHARMACEUTICALS LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
25.1 Prolong Pharmaceuticals LLC Business Profile
25.2 Prolong Pharmaceuticals LLC Ischemia Reperfusion Injury Drug Details
25.2.1 Drug Snapshot
25.2.1.1 Originator
25.2.1.2 Collaborator/Co-Developer
25.2.1.3 Route of Administration
25.2.1.4 Orphan Drug/Fast Track/Special Designation
25.2.1.5 Area
25.2.1.6 Type of Molecular Entity
25.3 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments
26. PROTHIX BV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
26.1 Prothix BV Business Profile
26.2 Prothix BV Ischemia Reperfusion Injury Drug Details
26.2.1 Drug Snapshot
26.2.1.1 Originator
26.2.1.2 Collaborator/Co-Developer
26.2.1.3 Route of Administration
26.2.1.4 Orphan Drug/Fast Track/Special Designation
26.2.1.5 Area
26.2.1.6 Type of Molecular Entity
26.3 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments
27. RADIKAL THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
27.1 Radikal Therapeutics Inc Business Profile
27.2 Radikal Therapeutics Inc Ischemia Reperfusion Injury Drug Details
27.2.1 Drug Snapshot
27.2.1.1 Originator
27.2.1.2 Collaborator/Co-Developer
27.2.1.3 Route of Administration
27.2.1.4 Orphan Drug/Fast Track/Special Designation
27.2.1.5 Area
27.2.1.6 Type of Molecular Entity
27.3 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments
28. SBI PHARMACEUTICALS CO LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
28.1 SBI Pharmaceuticals Co Ltd Business Profile
28.2 SBI Pharmaceuticals Co Ltd Ischemia Reperfusion Injury Drug Details
28.2.1 Drug Snapshot
28.2.1.1 Originator
28.2.1.2 Collaborator/Co-Developer
28.2.1.3 Route of Administration
28.2.1.4 Orphan Drug/Fast Track/Special Designation
28.2.1.5 Area
28.2.1.6 Type of Molecular Entity
28.3 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments
29. THERASOURCE LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
29.1 TheraSource LLC Business Profile
29.2 TheraSource LLC Ischemia Reperfusion Injury Drug Details
29.2.1 Drug Snapshot
29.2.1.1 Originator
29.2.1.2 Collaborator/Co-Developer
29.2.1.3 Route of Administration
29.2.1.4 Orphan Drug/Fast Track/Special Designation
29.2.1.5 Area
29.2.1.6 Type of Molecular Entity
29.3 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments
30. TRIM-EDICINE INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
30.1 TRIM-edicine Inc Business Profile
30.2 TRIM-edicine Inc Ischemia Reperfusion Injury Drug Details
30.2.1 Drug Snapshot
30.2.1.1 Originator
30.2.1.2 Collaborator/Co-Developer
30.2.1.3 Route of Administration
30.2.1.4 Orphan Drug/Fast Track/Special Designation
30.2.1.5 Area
30.2.1.6 Type of Molecular Entity
30.3 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments
31. X-IN8 BIOLOGICALS CORP ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
31.1 X-In8 Biologicals Corp Business Profile
31.2 X-In8 Biologicals Corp Ischemia Reperfusion Injury Drug Details
31.2.1 Drug Snapshot
31.2.1.1 Originator
31.2.1.2 Collaborator/Co-Developer
31.2.1.3 Route of Administration
31.2.1.4 Orphan Drug/Fast Track/Special Designation
31.2.1.5 Area
31.2.1.6 Type of Molecular Entity
31.3 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments
20. LATEST ISCHEMIA REPERFUSION INJURY DRUG PIPELINE DEVELOPMENTS, 2019
21. APPENDIX
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL ISCHEMIA REPERFUSION INJURY PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology
3. EXECUTIVE SUMMARY
3.1 Ischemia Reperfusion Injury Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Ischemia Reperfusion Injury pipeline, H1- 2019
3.5 Mechanism of Action wise Ischemia Reperfusion Injury Pipeline Candidates
4. ACELEROX LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
4.1 Acelerox LLC Business Profile
4.2 Acelerox LLC Ischemia Reperfusion Injury Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5. AMYNDAS PHARMACEUTICALS LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
5.1 Amyndas Pharmaceuticals LLC Business Profile
5.2 Amyndas Pharmaceuticals LLC Ischemia Reperfusion Injury Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6. ANGION BIOMEDICA CORP ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
6.1 Angion Biomedica Corp Business Profile
6.2 Angion Biomedica Corp Ischemia Reperfusion Injury Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7. ARCH ONCOLOGY ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
7.1 Arch Oncology Business Profile
7.2 Arch Oncology Ischemia Reperfusion Injury Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8. ARMARON BIO PTY LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
8.1 Armaron Bio Pty Ltd Business Profile
8.2 Armaron Bio Pty Ltd Ischemia Reperfusion Injury Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9. BIOMEDCORE INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
9.1 BioMedCore Inc Business Profile
9.2 BioMedCore Inc Ischemia Reperfusion Injury Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10. BOLDER BIOTECHNOLOGY INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
10.1 Bolder Biotechnology Inc Business Profile
10.2 Bolder Biotechnology Inc Ischemia Reperfusion Injury Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11. CATALYST BIOSCIENCES INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
11.1 Catalyst Biosciences Inc Business Profile
11.2 Catalyst Biosciences Inc Ischemia Reperfusion Injury Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12. CELDARA MEDICAL LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
12.1 Celdara Medical LLC Business Profile
12.2 Celdara Medical LLC Ischemia Reperfusion Injury Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13. CELLMID LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
13.1 Cellmid Ltd Business Profile
13.2 Cellmid Ltd Ischemia Reperfusion Injury Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14. CFM PHARMA HOLDING BV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
14.1 CFM Pharma Holding BV Business Profile
14.2 CFM Pharma Holding BV Ischemia Reperfusion Injury Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15. CONATUS PHARMACEUTICALS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
15.1 Conatus Pharmaceuticals Inc Business Profile
15.2 Conatus Pharmaceuticals Inc Ischemia Reperfusion Injury Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. CORLINE BIOMEDICAL AB ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
16.1 Corline Biomedical AB Business Profile
16.2 Corline Biomedical AB Ischemia Reperfusion Injury Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments
17. FARADAY PHARMACEUTICALS ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
17.1 Faraday Pharmaceuticals Business Profile
17.2 Faraday Pharmaceuticals Ischemia Reperfusion Injury Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments
18. GLUCOX BIOTECH AB ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
18.1 Glucox Biotech AB Business Profile
18.2 Glucox Biotech AB Ischemia Reperfusion Injury Drug Details
18.2.1 Drug Snapshot
18.2.1.1 Originator
18.2.1.2 Collaborator/Co-Developer
18.2.1.3 Route of Administration
18.2.1.4 Orphan Drug/Fast Track/Special Designation
18.2.1.5 Area
18.2.1.6 Type of Molecular Entity
18.3 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments
19. ISCHEMIX INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
19.1 Ischemix Inc Business Profile
19.2 Ischemix Inc Ischemia Reperfusion Injury Drug Details
19.2.1 Drug Snapshot
19.2.1.1 Originator
19.2.1.2 Collaborator/Co-Developer
19.2.1.3 Route of Administration
19.2.1.4 Orphan Drug/Fast Track/Special Designation
19.2.1.5 Area
19.2.1.6 Type of Molecular Entity
19.3 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments
20. MALLINCKRODT PLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
20.1 MallInckrodt Plc Business Profile
20.2 MallInckrodt Plc Ischemia Reperfusion Injury Drug Details
20.2.1 Drug Snapshot
20.2.1.1 Originator
20.2.1.2 Collaborator/Co-Developer
20.2.1.3 Route of Administration
20.2.1.4 Orphan Drug/Fast Track/Special Designation
20.2.1.5 Area
20.2.1.6 Type of Molecular Entity
20.3 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments
21. MIRAGEN THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
21.1 Miragen Therapeutics Inc Business Profile
21.2 Miragen Therapeutics Inc Ischemia Reperfusion Injury Drug Details
21.2.1 Drug Snapshot
21.2.1.1 Originator
21.2.1.2 Collaborator/Co-Developer
21.2.1.3 Route of Administration
21.2.1.4 Orphan Drug/Fast Track/Special Designation
21.2.1.5 Area
21.2.1.6 Type of Molecular Entity
21.3 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments
22. NOVELMED THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
22.1 NovelMed Therapeutics Inc Business Profile
22.2 NovelMed Therapeutics Inc Ischemia Reperfusion Injury Drug Details
22.2.1 Drug Snapshot
22.2.1.1 Originator
22.2.1.2 Collaborator/Co-Developer
22.2.1.3 Route of Administration
22.2.1.4 Orphan Drug/Fast Track/Special Designation
22.2.1.5 Area
22.2.1.6 Type of Molecular Entity
22.3 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments
23. OPSONA THERAPEUTICS LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
23.1 Opsona Therapeutics Ltd Business Profile
23.2 Opsona Therapeutics Ltd Ischemia Reperfusion Injury Drug Details
23.2.1 Drug Snapshot
23.2.1.1 Originator
23.2.1.2 Collaborator/Co-Developer
23.2.1.3 Route of Administration
23.2.1.4 Orphan Drug/Fast Track/Special Designation
23.2.1.5 Area
23.2.1.6 Type of Molecular Entity
23.3 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments
24. PHARMING GROUP NV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
24.1 Pharming Group NV Business Profile
24.2 Pharming Group NV Ischemia Reperfusion Injury Drug Details
24.2.1 Drug Snapshot
24.2.1.1 Originator
24.2.1.2 Collaborator/Co-Developer
24.2.1.3 Route of Administration
24.2.1.4 Orphan Drug/Fast Track/Special Designation
24.2.1.5 Area
24.2.1.6 Type of Molecular Entity
24.3 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments
25. PROLONG PHARMACEUTICALS LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
25.1 Prolong Pharmaceuticals LLC Business Profile
25.2 Prolong Pharmaceuticals LLC Ischemia Reperfusion Injury Drug Details
25.2.1 Drug Snapshot
25.2.1.1 Originator
25.2.1.2 Collaborator/Co-Developer
25.2.1.3 Route of Administration
25.2.1.4 Orphan Drug/Fast Track/Special Designation
25.2.1.5 Area
25.2.1.6 Type of Molecular Entity
25.3 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments
26. PROTHIX BV ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
26.1 Prothix BV Business Profile
26.2 Prothix BV Ischemia Reperfusion Injury Drug Details
26.2.1 Drug Snapshot
26.2.1.1 Originator
26.2.1.2 Collaborator/Co-Developer
26.2.1.3 Route of Administration
26.2.1.4 Orphan Drug/Fast Track/Special Designation
26.2.1.5 Area
26.2.1.6 Type of Molecular Entity
26.3 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments
27. RADIKAL THERAPEUTICS INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
27.1 Radikal Therapeutics Inc Business Profile
27.2 Radikal Therapeutics Inc Ischemia Reperfusion Injury Drug Details
27.2.1 Drug Snapshot
27.2.1.1 Originator
27.2.1.2 Collaborator/Co-Developer
27.2.1.3 Route of Administration
27.2.1.4 Orphan Drug/Fast Track/Special Designation
27.2.1.5 Area
27.2.1.6 Type of Molecular Entity
27.3 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments
28. SBI PHARMACEUTICALS CO LTD ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
28.1 SBI Pharmaceuticals Co Ltd Business Profile
28.2 SBI Pharmaceuticals Co Ltd Ischemia Reperfusion Injury Drug Details
28.2.1 Drug Snapshot
28.2.1.1 Originator
28.2.1.2 Collaborator/Co-Developer
28.2.1.3 Route of Administration
28.2.1.4 Orphan Drug/Fast Track/Special Designation
28.2.1.5 Area
28.2.1.6 Type of Molecular Entity
28.3 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments
29. THERASOURCE LLC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
29.1 TheraSource LLC Business Profile
29.2 TheraSource LLC Ischemia Reperfusion Injury Drug Details
29.2.1 Drug Snapshot
29.2.1.1 Originator
29.2.1.2 Collaborator/Co-Developer
29.2.1.3 Route of Administration
29.2.1.4 Orphan Drug/Fast Track/Special Designation
29.2.1.5 Area
29.2.1.6 Type of Molecular Entity
29.3 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments
30. TRIM-EDICINE INC ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
30.1 TRIM-edicine Inc Business Profile
30.2 TRIM-edicine Inc Ischemia Reperfusion Injury Drug Details
30.2.1 Drug Snapshot
30.2.1.1 Originator
30.2.1.2 Collaborator/Co-Developer
30.2.1.3 Route of Administration
30.2.1.4 Orphan Drug/Fast Track/Special Designation
30.2.1.5 Area
30.2.1.6 Type of Molecular Entity
30.3 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments
31. X-IN8 BIOLOGICALS CORP ISCHEMIA REPERFUSION INJURY PIPELINE DETAILS
31.1 X-In8 Biologicals Corp Business Profile
31.2 X-In8 Biologicals Corp Ischemia Reperfusion Injury Drug Details
31.2.1 Drug Snapshot
31.2.1.1 Originator
31.2.1.2 Collaborator/Co-Developer
31.2.1.3 Route of Administration
31.2.1.4 Orphan Drug/Fast Track/Special Designation
31.2.1.5 Area
31.2.1.6 Type of Molecular Entity
31.3 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments
20. LATEST ISCHEMIA REPERFUSION INJURY DRUG PIPELINE DEVELOPMENTS, 2019
21. APPENDIX
21.1 About Us
21.2 Sources and Methodology
21.3 Contact Information
